| abstract |
The present invention provides a nucleic acid having a performance inhibitory activity of complement factor B, a pharmaceutical composition comprising the nucleic acid, and atypical hemolytic uremic syndrome comprising the nucleic acid, paroxysmal nocturnal hemoglobinuria, senile macular degeneration, Membranous proliferative spheroid nephritis, C3 nephritis, membranous nephropathy, rapid progressive glomerulonephritis (RPGN), acute renal failure (AKI), ANCA-associated vasculitis, lupus nephritis, asthma or autoimmune disease prevention or Therapeutic medicine. |